[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Siegel, R.L., Giaquinto, A.N. and Jemal, A. (2024) Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians, 74, 12-49. https://doi.org/10.3322/caac.21820
|
[3]
|
Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., et al. (1989) Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer. Science, 244, 707-712. https://doi.org/10.1126/science.2470152
|
[4]
|
Bogoevska, V., Wolters-Eisfeld, G., Hofmann, B.T., El Gammal, A.T., Mercanoglu, B., Gebauer, F., et al. (2016) HRG/HER2/HER3 Signaling Promotes Ahr-Mediated Memo-1 Expression and Migration in Colorectal Cancer. Oncogene, 36, 2394-2404. https://doi.org/10.1038/onc.2016.390
|
[5]
|
Fanotto, V., Ongaro, E., Rihawi, K., Avallone, A., Silvestris, N., Fornaro, L., et al. (2016) HER-2 Inhibition in Gastric and Colorectal Cancers: Tangible Achievements, Novel Acquisitions and Future Perspectives. Oncotarget, 7, 69060-69074. https://doi.org/10.18632/oncotarget.11264
|
[6]
|
Yang, D., Wang, B., Li, Y., Zhang, J., Gong, X., Qin, H., et al. (2023) HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration. Biomedicines, 11, Article No. 2889. https://doi.org/10.3390/biomedicines11112889
|
[7]
|
Afrăsânie, V., Marinca, M.V., Alexa-Stratulat, T., Gafton, B., Păduraru, M., Adavidoaiei, A.M., et al. (2019) KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer—Practical Implications for the Clinician. Radiology and Oncology, 53, 265-274. https://doi.org/10.2478/raon-2019-0033
|
[8]
|
Ross, J.S., Fakih, M., Ali, S.M., Elvin, J.A., Schrock, A.B., Suh, J., et al. (2018) Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in erbb2 and erbb3. Cancer, 124, 1358-1373. https://doi.org/10.1002/cncr.31125
|
[9]
|
Indini, A., Rijavec, E. and Grossi, F. (2021) Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. International Journal of Molecular Sciences, 22, Article No. 4774. https://doi.org/10.3390/ijms22094774
|
[10]
|
Battaglin, F., Ou, F., Qu, X., Hochster, H.S., Niedzwiecki, D., Goldberg, R.M., et al. (2024) her2 Gene Expression Levels Are Predictive and Prognostic in Patients with Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. Journal of Clinical Oncology, 42, 1890-1902. https://doi.org/10.1200/jco.23.01507
|
[11]
|
Wang, R., Dai, W., Gong, J., Huang, M., Hu, T., Li, H., et al. (2022) Development of a Novel Combined Nomogram Model Integrating Deep Learning-Pathomics, Radiomics and Immunoscore to Predict Postoperative Outcome of Colorectal Cancer Lung Metastasis Patients. Journal of Hematology & Oncology, 15, Article No. 11. https://doi.org/10.1186/s13045-022-01225-3
|
[12]
|
Huang, Y., Liang, C., He, L., Tian, J., Liang, C., Chen, X., et al. (2016) Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. Journal of Clinical Oncology, 34, 2157-2164. https://doi.org/10.1200/jco.2015.65.9128
|
[13]
|
Bae, T., Hallis, S.P. and Kwak, M. (2024) Hypoxia, Oxidative Stress, and the Interplay of HIFs and NRF2 Signaling in Cancer. Experimental & Molecular Medicine, 56, 501-514. https://doi.org/10.1038/s12276-024-01180-8
|
[14]
|
Kazi, A.A., Gilani, R.A., Schech, A.J., Chumsri, S., Sabnis, G., Shah, P., et al. (2014) Nonhypoxic Regulation and Role of Hypoxia-Inducible Factor 1 in Aromatase Inhibitor Resistant Breast Cancer. Breast Cancer Research, 16, R15. https://doi.org/10.1186/bcr3609
|
[15]
|
Srikantia, S.G., Bhaskaram, C., Prasad, J.S. and Krishnamachari, K.A.V.R. (1976) ANÆMIA and IMMUNE Response. The Lancet, 307, 1307-1309. https://doi.org/10.1016/s0140-6736(76)92647-7
|
[16]
|
La Vecchia, S. and Sebastián, C. (2020) Metabolic Pathways Regulating Colorectal Cancer Initiation and Progression. Seminars in Cell & Developmental Biology, 98, 63-70. https://doi.org/10.1016/j.semcdb.2019.05.018
|
[17]
|
Strickler, J.H., Yoshino, T., Graham, R.P., Siena, S. and Bekaii-Saab, T. (2022) Diagnosis and Treatment of Erbb2-Positive Metastatic Colorectal Cancer: A Review. JAMA Oncology, 8, 760-769. https://doi.org/10.1001/jamaoncol.2021.8196
|
[18]
|
Sell, T., Klotz, C., Fischer, M.M., Astaburuaga-García, R., Krug, S., Drost, J., et al. (2023) Oncogenic Signaling Is Coupled to Colorectal Cancer Cell Differentiation State. Journal of Cell Biology, 222, e202204001. https://doi.org/10.1083/jcb.202204001
|
[19]
|
Abdul Razzaq, E.A., Venkatachalam, T., Bajbouj, K., Rahmani, M., Mahdami, A., Rawat, S., et al. (2021) HER2 Overexpression Is a Putative Diagnostic and Prognostic Biomarker for Late-Stage Colorectal Cancer in North African Patients. Libyan Journal of Medicine, 16, Article ID: 1955462. https://doi.org/10.1080/19932820.2021.1955462
|
[20]
|
Cunningham, D., Atkin, W., Lenz, H., Lynch, H.T., Minsky, B., Nordlinger, B., et al. (2010) Colorectal Cancer. The Lancet, 375, 1030-1047. https://doi.org/10.1016/s0140-6736(10)60353-4
|
[21]
|
Geng, Y., Wang, J., Wang, R., Wang, K., Xu, Y., Song, G., et al. (2012) Leptin and HER-2 Are Associated with Gastric Cancer Progression and Prognosis of Patients. Biomedicine & Pharmacotherapy, 66, 419-424. https://doi.org/10.1016/j.biopha.2012.03.002
|
[22]
|
Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., et al. (1997) The Expression of P185(her-2/neu) Correlates with the Stage of Disease and Survival in Colorectal Cancer. Gastroenterology, 112, 1103-1113. https://doi.org/10.1016/s0016-5085(97)70120-3
|
[23]
|
Yan, S. (2011) Clinicopathologic Significance of Her-2/neu Protein Expression and Gene Amplification in Gastric Carcinoma. World Journal of Gastroenterology, 17, 1501-1506. https://doi.org/10.3748/wjg.v17.i11.1501
|
[24]
|
Hao, R., Liu, Y., Du, Q., Liu, L., Chen, S., You, H., et al. (2019) Transgelin-2 Expression in Breast Cancer and Its Relationships with Clinicopathological Features and Patient Outcome. Breast Cancer, 26, 776-783. https://doi.org/10.1007/s12282-019-00981-4
|
[25]
|
Raghav, K.P.S. and Moasser, M.M. (2022) Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Clinical Cancer Research, 29, 2351-2361. https://doi.org/10.1158/1078-0432.ccr-22-0283
|